期刊文献+

蛋白酶体抑制剂对神经细胞前咽缺陷蛋白-1表达的影响

The effect of proteasomal inhibitors on anterior pharynx decfective-1 expression in neuronal cells
原文传递
导出
摘要 目的 探讨神经细胞内前咽缺陷蛋白-1(Aph-1)的蛋白降解是经蛋白酶体途径还是经溶酶体途径介导.方法 在人神经母细胞瘤细胞(SH-SY5Y)建立稳定表达Aph-1细胞株的基础上,应用蛋白酶体和溶酶体酶抑制剂分别处理Aph-1细胞株,并结合Western blotting、放射性同位素脉冲示踪技术(Pulse-chase)、免疫荧光双标等技术,检测细胞内Aph-1的蛋白表达变化.结果 Western blotting结果显示,特异性蛋白酶体抑制剂能显著提高神经细胞内源性和外源性Aph-1的蛋白表达水平,且高度特异的蛋白酶体抑制剂乳胞素(Lactacystin)对Aph-1表达的增强效应呈剂量依赖性和时间依赖性;而非蛋白酶体蛋白酶抑制剂ALLM和溶酶体酶抑制剂对Aph-1的蛋白表达无影响;Pulsechase结果显示,蛋白酶体抑制剂可增强细胞内新合成Aph-1的表达水平,其增强作用是通过阻止35S-Aph-1的蛋白降解实现;免疫荧光双标结果显示,Aph-1与泛素在细胞内共存.结论 神经细胞内Aph-1的蛋白降解由蛋白酶体途径介导,与溶酶体途径无关;Aph-1在降解之前经泛素化修饰. Objectives To investigate whether degradation of anterior pharynx decfective-1(Aph-1) goes through proteasomal pathway or lysosomal pathway.Methods Various methods such as cell culture,Western blotting,pulse-chase metabolic labeling technique,double immunofluoresecnt staining,combined with proteasomal and lysosomal inhibition were used to check Aph-1 expression level in stable Aph-1-transfected or non-transfected neuronal(SH-SY5Y)cell line.Results Using Western blotting,treating the neuronal cells with proteasome specific inhibitors significantly increased the expression of both endogenous and exogenous Aph-1.The effect of the proteasome inhibitors on Aph-1 expression was dose-and time-dependent Lysosomal pathway was not involved in Aph-1 degradation. Pulse-chase metabolic labeling experiment showed that the turnover of newly-synthesized radiolabeled Aph-1 protein was blocked by Lactacystin.Double immunofluorescent staining revealed colocalization of Aph-1 and ubiquitin in the same cells.Conclusion Degradation of Aph-1 protein is mediated by proteasomal pathway in neuronal cells,and is not related to lysosomal pathway.Aph-1 protein is ubiquitinated before degradation.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2010年第11期795-800,共6页 Chinese Journal of Neurology
基金 教育部重点项目资助计划(209102) 重庆市首届优秀人才资助计划(渝教人[2009]2号) 重庆市教委资助计划(KJ090328) 重庆医科大学重点课题资助项目(XBZD200702)
关键词 神经元 膜蛋白质类 蛋白酶抑制药 Neurons Membrane proteins Cysteine proteinase inhibitors
  • 相关文献

参考文献18

  • 1Wolfe MS.gamma-Secretase in biology and medicine.Semin Cell Dev Biol,2009,20:219-224.
  • 2魏翠柏,贾建平.阿尔茨海默病中α分泌酶的研究进展[J].中华神经科杂志,2006,39(6):421-423. 被引量:3
  • 3Selkoe DJ,Wolfe MS.Presenilin:running with scissors in the membrane.Cell,2007,131:215-221.
  • 4De Strooper B.Aph-1,Pen-2,and Nicastrin with Presenilin generate an active gamma-Secretase complex.Neuron,2003,38:9-12.
  • 5Spasic D,Annaert W.Building gamma-secretase:the bits and pieces.J Cell Sci,2008,121 Pt4:413-420.
  • 6Kimberly WT,LaVoie MJ,Ostaszewski BL,et al.Gammasecretase is a membrane protein complex comprised of presenilin,nicastrin,Aph-1,and Pen-2.Proc Natl Acad Sci U S A,2003,100:6382-6387.
  • 7Steiner H,Winkler E,Haass C.Chemical cross-linking provides a model of the gamma-secretase complex subunit architecture and evidence for close proximity of the C-terminal fragment of presenilin with APH-1.J Biol Chem,2008,283:34677-34686.
  • 8Francis R,McGrath G,Zhang J,et al.aph-1 and pen-2 are required for Notch pathway signaling,gamma-secretase cleavage of betaAPP,and presenilin protein accumulation.Dev Cell,2002,3:85-97.
  • 9Shirotani K,Edbauer D,Prokop S,et al.Identification of distinct gamma-secretase complexes with different APH-1 variants.J Biol Chem,2004,279:41340-41345.
  • 10Ma G,Li T,Price DL,et al.APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development.J Neurosci,2005,25:192-198.

二级参考文献19

  • 1Colciaghi F,Marcello E,Borroni B,et al.Platelet APP,ADAM 10 and BACE alterations in the early stages of Alzheimer disease.Neurology,2004,62:498-501.
  • 2Stein TD,Anders NJ,DeCarli C,et al.Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons:support for the amyloid hypothesis.J Neurosci,2004,4:7707-7717.
  • 3Hooper NM,Parvathy S,Karran EH,et al.Angiotensin-converting enzyme and the amyloid precursor protein secretases.Biochem Soc Trans,1999,27:229-234.
  • 4Asai M,Hattori C,Szabo B,et al.Putative function of ADAM9,ADAM10,and ADAM17 as APP alpha-secretase.Biochem Biophys Res Commun,2003,301:231-235.
  • 5Kojro E,Fahrenholz F.The non-amyloidogenic pathway:structure and function of alpha-secretases.Subcell Biochem,2005,38:105-127.
  • 6Di Luca M,Grossi E,Borroni B,et al.Artificial neural networks allow the use of simultaneous measurements of Alzheimer disease markers for early detection of the disease.J Transl Med,2005,3:30.
  • 7Kojro E,Gimpl G,Lammich S,et al.Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.Proc Natl Acad Sci USA,2001,98:5815-5820.
  • 8Hartmann D,de Strooper B,Serneels L,et al.The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts.Hum Mol Genet,2002,11:2615-2624.
  • 9Hotoda N,Koike H,Sasagawa N,et al.A secreted form of human ADAM9 has an alpha-secretase activity for APP.Biochem Biophys Res Commun,2002,293:800-805.
  • 10Fahrenholz F,Gilbert S,Kojro E,et al.Alpha-secretase activity of the disintegrin metalloprotease ADAM 10.Influences of domain structure.Ann N Y Acad Sci,2000,920:215-222.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部